{"id":"W2946105917","doi":"10.1093/eurheartj/ehz299","title":"Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta; St. Michael's Hospital","funders":"American Regent; Genentech; Esperion Therapeutics; Idorsia Pharmaceuticals; Duke Clinical Research Institute; Astellas Pharma; Eisai; Bayer HealthCare; Medicines Company; Regado Biosciences; Verily Life Sciences; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; St. Jude Medical; Flatiron Health; Green Lane Research and Educational Fund; Regeneron Pharmaceuticals; Abbott Vascular; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; Belvoir Media Group; Novo Nordisk; MyoKardia; Janssen Pharmaceuticals; Ablynx; Daiichi Sankyo Europe; Servier; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Sanofi; American Heart Association","keywords":"Medicine; Alirocumab; Myocardial infarction; Cardiology; Internal medicine; PCSK9; Intensive care medicine; Cholesterol; Lipoprotein; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006984467,0.0001185526,0.0005020606,0.000063707,0.00007391877,0.00001593158,0.0001052702,0.00003765454,0.00008637957],"category_scores_gemma":[0.0002111985,0.00006531196,0.0005133059,0.00009954134,0.00004003601,0.00004995084,0.00003653113,0.0003955229,0.0001371735],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002739656,"about_ca_system_score_gemma":0.0001097063,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005939828,"about_ca_topic_score_gemma":0.000001078813,"domain_scores_codex":[0.9980276,0.0006966688,0.0003610605,0.0001340641,0.0006435417,0.0001370261],"domain_scores_gemma":[0.9989725,0.0002399734,0.0001676186,0.0004138489,0.0000971797,0.0001088779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1355695,0.004371631,0.5235396,0.001839776,0.02024495,0.00122762,0.01244746,0.0005826964,0.09719404,0.003152876,0.06651891,0.1333109],"study_design_scores_gemma":[0.02882151,0.002164553,0.9143604,0.0003107719,0.0002306172,0.0001038237,0.00006103925,0.000004044525,0.002877522,0.00004646277,0.05092786,0.00009137941],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916058,0.001113042,0.00002070919,0.0007750729,0.001506971,0.0005805728,0.000002399066,0.00001178162,0.004383634],"genre_scores_gemma":[0.9965478,0.0001452221,0.00009361615,0.0009279362,0.002079666,0.000001414264,0.000002392175,0.00002594675,0.0001760668],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3908208,"threshold_uncertainty_score":0.2663344,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01707089362362753,"score_gpt":0.2683105716992243,"score_spread":0.2512396780755968,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}